|
WO2013066438A2
(en)
|
2011-07-22 |
2013-05-10 |
President And Fellows Of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
JP6219832B2
(ja)
|
2011-10-17 |
2017-10-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
細胞内送達
|
|
WO2013163628A2
(en)
|
2012-04-27 |
2013-10-31 |
Duke University |
Genetic correction of mutated genes
|
|
US9828582B2
(en)
|
2013-03-19 |
2017-11-28 |
Duke University |
Compositions and methods for the induction and tuning of gene expression
|
|
US20150044192A1
(en)
|
2013-08-09 |
2015-02-12 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a cas9 nuclease
|
|
PL3033184T3
(pl)
|
2013-08-16 |
2021-09-20 |
Massachusetts Institute Of Technology |
Selektywne dostarczanie materiału do komórek
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9388430B2
(en)
|
2013-09-06 |
2016-07-12 |
President And Fellows Of Harvard College |
Cas9-recombinase fusion proteins and uses thereof
|
|
US9737604B2
(en)
|
2013-09-06 |
2017-08-22 |
President And Fellows Of Harvard College |
Use of cationic lipids to deliver CAS9
|
|
US9340799B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
MRNA-sensing switchable gRNAs
|
|
KR20230054509A
(ko)
|
2013-11-07 |
2023-04-24 |
에디타스 메디신, 인코포레이티드 |
지배적인 gRNA를 이용하는 CRISPR-관련 방법 및 조성물
|
|
US11053481B2
(en)
|
2013-12-12 |
2021-07-06 |
President And Fellows Of Harvard College |
Fusions of Cas9 domains and nucleic acid-editing domains
|
|
MX2017000646A
(es)
|
2014-07-15 |
2017-04-27 |
Juno Therapeutics Inc |
Celulas geneticamente modificadas para terapia celular adoptiva.
|
|
AU2015298571B2
(en)
|
2014-07-30 |
2020-09-03 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
EP4427809A3
(en)
*
|
2014-10-31 |
2024-12-04 |
The Trustees of The University of Pennsylvania |
Altering gene expression in car-t cells and uses thereof
|
|
JP7523203B2
(ja)
|
2014-10-31 |
2024-07-26 |
マサチューセッツ インスティテュート オブ テクノロジー |
生体分子の免疫細胞への送達
|
|
US10526573B2
(en)
|
2014-11-14 |
2020-01-07 |
Massachusetts Institute Of Technology |
Disruption and field enabled delivery of compounds and compositions into cells
|
|
WO2016094880A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Delivery, use and therapeutic applications of crispr systems and compositions for genome editing as to hematopoietic stem cells (hscs)
|
|
EP3889260A1
(en)
|
2014-12-12 |
2021-10-06 |
The Broad Institute, Inc. |
Protected guide rnas (pgrnas)
|
|
CN107532162A
(zh)
|
2014-12-12 |
2018-01-02 |
托德·M·伍尔夫 |
用于利用寡核苷酸编辑细胞中核酸的组合物和方法
|
|
WO2016094874A1
(en)
|
2014-12-12 |
2016-06-16 |
The Broad Institute Inc. |
Escorted and functionalized guides for crispr-cas systems
|
|
EP3237615B2
(en)
|
2014-12-24 |
2023-07-26 |
The Broad Institute, Inc. |
Crispr having or associated with destabilization domains
|
|
EP3245294A4
(en)
|
2015-01-12 |
2018-05-30 |
Massachusetts Institute of Technology |
Gene editing through microfluidic delivery
|
|
EP3256487A4
(en)
|
2015-02-09 |
2018-07-18 |
Duke University |
Compositions and methods for epigenome editing
|
|
WO2016154596A1
(en)
*
|
2015-03-25 |
2016-09-29 |
Editas Medicine, Inc. |
Crispr/cas-related methods, compositions and components
|
|
BR112017020750A2
(pt)
*
|
2015-03-27 |
2018-06-26 |
Harvard College |
células t modificadas e métodos de produção e utilização das mesmas
|
|
HK1254190A1
(zh)
|
2015-05-08 |
2019-07-12 |
President And Fellows Of Harvard College |
通用供体干细胞和相关方法
|
|
EP3294888A1
(en)
*
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating hiv infection and aids
|
|
EP3294896A1
(en)
*
|
2015-05-11 |
2018-03-21 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
WO2016196388A1
(en)
|
2015-05-29 |
2016-12-08 |
Juno Therapeutics, Inc. |
Composition and methods for regulating inhibitory interactions in genetically engineered cells
|
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
AU2016279062A1
(en)
|
2015-06-18 |
2019-03-28 |
Omar O. Abudayyeh |
Novel CRISPR enzymes and systems
|
|
JP6925984B2
(ja)
|
2015-07-09 |
2021-08-25 |
マサチューセッツ インスティテュート オブ テクノロジー |
無核細胞への物質の送達
|
|
MA42895A
(fr)
|
2015-07-15 |
2018-05-23 |
Juno Therapeutics Inc |
Cellules modifiées pour thérapie cellulaire adoptive
|
|
US10906951B2
(en)
|
2015-07-29 |
2021-02-02 |
Onk Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
EP3971284B1
(en)
|
2015-07-29 |
2023-11-08 |
ONK Therapeutics Limited |
Modified natural killer cells and natural killer cell lines having increased cytotoxicity
|
|
GB2557123B
(en)
|
2015-07-31 |
2021-11-03 |
Univ Minnesota |
Modified cells and methods of therapy
|
|
WO2017041051A1
(en)
|
2015-09-04 |
2017-03-09 |
Sqz Biotechnologies Company |
Intracellular delivery of biomolecules to cells comprising a cell wall
|
|
EP4089175A1
(en)
|
2015-10-13 |
2022-11-16 |
Duke University |
Genome engineering with type i crispr systems in eukaryotic cells
|
|
US12043852B2
(en)
|
2015-10-23 |
2024-07-23 |
President And Fellows Of Harvard College |
Evolved Cas9 proteins for gene editing
|
|
CA3001711A1
(en)
|
2015-10-30 |
2017-05-04 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for treating herpes simplex virus
|
|
MX2018005377A
(es)
|
2015-11-30 |
2018-11-09 |
Univ Duke |
Dianas terapeuticas para la correccion del gen de la distrofina humana por edicion genica y metodos de uso.
|
|
JP2018536436A
(ja)
*
|
2015-12-04 |
2018-12-13 |
ノバルティス アーゲー |
免疫腫瘍学のための組成物および方法
|
|
CN116218916A
(zh)
*
|
2016-01-12 |
2023-06-06 |
Sqz生物技术公司 |
复合物的细胞内递送
|
|
WO2017147278A1
(en)
|
2016-02-25 |
2017-08-31 |
The Children's Medical Center Corporation |
Customized class switch of immunoglobulin genes in lymphoma and hybridoma by crispr/cas9 technology
|
|
SG11201807538PA
(en)
*
|
2016-03-04 |
2018-09-27 |
Editas Medicine Inc |
Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
|
|
EP3219799A1
(en)
|
2016-03-17 |
2017-09-20 |
IMBA-Institut für Molekulare Biotechnologie GmbH |
Conditional crispr sgrna expression
|
|
KR20190080825A
(ko)
*
|
2016-03-21 |
2019-07-08 |
다나-파버 캔서 인스티튜트 인크. |
T-세포 기능소실 상태-특이적 유전자 발현 조절인자 및 그 용도
|
|
WO2017180915A2
(en)
|
2016-04-13 |
2017-10-19 |
Duke University |
Crispr/cas9-based repressors for silencing gene targets in vivo and methods of use
|
|
EP3445375A1
(en)
*
|
2016-04-22 |
2019-02-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for treatment of diseases associated with trinucleotide repeats in transcription factor four
|
|
CN107304434A
(zh)
*
|
2016-04-25 |
2017-10-31 |
上海宇玫博生物科技有限公司 |
一种免疫细胞治疗的双功能新型载体
|
|
CA3022319A1
(en)
*
|
2016-05-06 |
2017-11-09 |
Tod M. Woolf |
Improved methods for genome editing with and without programmable nucleases
|
|
SG11201809710RA
(en)
*
|
2016-05-06 |
2018-11-29 |
Juno Therapeutics Inc |
Genetically engineered cells and methods of making the same
|
|
US10912287B2
(en)
|
2016-06-28 |
2021-02-09 |
Biocytogen Pharmaceuticals (Beijing) Co., Ltd |
Genetically modified mice expressing humanized PD-1
|
|
EP3487523B1
(en)
|
2016-07-19 |
2023-09-06 |
Duke University |
Therapeutic applications of cpf1-based genome editing
|
|
KR20250103795A
(ko)
|
2016-08-03 |
2025-07-07 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
아데노신 핵염기 편집제 및 그의 용도
|
|
US12350349B2
(en)
*
|
2016-08-03 |
2025-07-08 |
Washington University |
Gene editing of CAR-T cells for the treatment of T cell malignancies with chimeric antigen receptors
|
|
US11078481B1
(en)
|
2016-08-03 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for screening for cancer targets
|
|
CN109804066A
(zh)
|
2016-08-09 |
2019-05-24 |
哈佛大学的校长及成员们 |
可编程cas9-重组酶融合蛋白及其用途
|
|
US11352647B2
(en)
|
2016-08-17 |
2022-06-07 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
CN109803977B
(zh)
|
2016-08-17 |
2023-03-17 |
菲克特生物科学股份有限公司 |
核酸产品及其施用方法
|
|
US11542509B2
(en)
|
2016-08-24 |
2023-01-03 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
US11078483B1
(en)
|
2016-09-02 |
2021-08-03 |
KSQ Therapeutics, Inc. |
Methods for measuring and improving CRISPR reagent function
|
|
AU2017338827B2
(en)
|
2016-10-03 |
2023-08-31 |
Juno Therapeutics, Inc. |
HPV-specific binding molecules
|
|
KR20190084053A
(ko)
|
2016-10-13 |
2019-07-15 |
주노 쎄러퓨티크스 인코퍼레이티드 |
트립토판 대사 경로 조절인자 관련 면역 치료 방법 및 조성물
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
CN110520530A
(zh)
|
2016-10-18 |
2019-11-29 |
明尼苏达大学董事会 |
肿瘤浸润性淋巴细胞和治疗方法
|
|
WO2018081476A2
(en)
*
|
2016-10-27 |
2018-05-03 |
Intima Bioscience, Inc. |
Viral methods of t cell therapy
|
|
US11332713B2
(en)
|
2016-11-16 |
2022-05-17 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
US11261428B2
(en)
|
2018-03-15 |
2022-03-01 |
KSQ Therapeutics, Inc. |
Gene-regulating compositions and methods for improved immunotherapy
|
|
BR112019010486A2
(pt)
|
2016-11-28 |
2019-09-10 |
Napajen Pharma Inc |
sirna quimicamente modificado
|
|
CN110249046A
(zh)
|
2016-12-05 |
2019-09-17 |
朱诺治疗学股份有限公司 |
用于过继细胞疗法的工程化细胞的产生
|
|
JP7206214B2
(ja)
|
2016-12-13 |
2023-01-17 |
シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） |
インビトロ及びインビボで操作された細胞において発現された化学誘導シグナル伝達複合体の外因性薬物活性化の方法
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
CN110913870A
(zh)
*
|
2016-12-30 |
2020-03-24 |
细胞结构公司 |
遗传修饰的自然杀伤细胞
|
|
WO2018140890A1
(en)
*
|
2017-01-29 |
2018-08-02 |
Zequn Tang |
Methods of immune modulation against foreign and/or auto antigens
|
|
TW201839136A
(zh)
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CA3054307A1
(en)
|
2017-02-22 |
2018-08-30 |
Io Biosciences, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
|
US10828330B2
(en)
*
|
2017-02-22 |
2020-11-10 |
IO Bioscience, Inc. |
Nucleic acid constructs comprising gene editing multi-sites and uses thereof
|
|
EP3592381A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Cancer vaccine
|
|
EP3592853A1
(en)
|
2017-03-09 |
2020-01-15 |
President and Fellows of Harvard College |
Suppression of pain by gene editing
|
|
KR20190127797A
(ko)
|
2017-03-10 |
2019-11-13 |
프레지던트 앤드 펠로우즈 오브 하바드 칼리지 |
시토신에서 구아닌으로의 염기 편집제
|
|
MX2019011272A
(es)
*
|
2017-03-22 |
2019-10-24 |
Novartis Ag |
Composiciones y metodos para inmunooncologia.
|
|
CA3057192A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
WO2018191490A1
(en)
*
|
2017-04-13 |
2018-10-18 |
The Trustees Of The University Of Pennsylvania |
Use of gene editing to generate universal tcr re-directed t cells for adoptive immunotherapy
|
|
US11166985B2
(en)
|
2017-05-12 |
2021-11-09 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
MY201573A
(en)
|
2017-05-12 |
2024-03-02 |
Crispr Therapeutics Ag |
Materials and methods for engineering cells and uses thereof in immuno-oncology
|
|
WO2018209320A1
(en)
|
2017-05-12 |
2018-11-15 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide rnas for use with crispr-cas9 in genome editing and transcriptional activation
|
|
KR102590466B1
(ko)
|
2017-05-25 |
2023-10-19 |
2세븐티 바이오, 인코포레이티드 |
Cblb 엔도뉴클레아제 변이체, 조성물 및 사용 방법
|
|
CN110997908A
(zh)
|
2017-06-09 |
2020-04-10 |
爱迪塔斯医药公司 |
工程化的cas9核酸酶
|
|
KR102720855B1
(ko)
|
2017-06-15 |
2024-10-25 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
표적화된 비-바이러스 dna 삽입
|
|
WO2018233596A1
(zh)
*
|
2017-06-20 |
2018-12-27 |
江苏恒瑞医药股份有限公司 |
体外敲除T细胞中靶基因的方法以及该方法中使用的crRNA
|
|
SG10201705285SA
(en)
*
|
2017-06-27 |
2019-01-30 |
Agency Science Tech & Res |
Antisense oligonucleotides
|
|
WO2019006418A2
(en)
|
2017-06-30 |
2019-01-03 |
Intima Bioscience, Inc. |
ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
|
|
US20200140896A1
(en)
*
|
2017-06-30 |
2020-05-07 |
Novartis Ag |
Methods for the treatment of disease with gene editing systems
|
|
CN111801345A
(zh)
|
2017-07-28 |
2020-10-20 |
哈佛大学的校长及成员们 |
使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
JP7654240B2
(ja)
|
2017-09-19 |
2025-04-01 |
マサチューセッツ インスティテュート オブ テクノロジー |
キメラ抗原受容体ｔ細胞治療のための組成物およびその使用
|
|
WO2019070541A1
(en)
|
2017-10-03 |
2019-04-11 |
Juno Therapeutics, Inc. |
HPV-SPECIFIC BINDING MOLECULES
|
|
WO2019072241A1
(en)
|
2017-10-13 |
2019-04-18 |
Beijing Biocytogen Co., Ltd |
NON-HUMAN ANIMAL GENETICALLY MODIFIED WITH PD-1 HUMAN OR CHIMERIC
|
|
CA3082251A1
(en)
|
2017-10-16 |
2019-04-25 |
The Broad Institute, Inc. |
Uses of adenosine base editors
|
|
KR102503130B1
(ko)
|
2017-10-27 |
2023-02-24 |
더 리전트 오브 더 유니버시티 오브 캘리포니아 |
내인성 t 세포 수용체의 표적화된 대체
|
|
WO2019089982A1
(en)
|
2017-11-01 |
2019-05-09 |
Juno Therapeutics, Inc. |
Method of assessing activity of recombinant antigen receptors
|
|
CN111556893A
(zh)
*
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
|
US20210187018A1
(en)
*
|
2017-12-07 |
2021-06-24 |
Flagship Pioneering Innovations V, Inc. |
Cytobiologics and therapeutic uses thereof
|
|
WO2019118508A1
(en)
|
2017-12-12 |
2019-06-20 |
The Trustees Of The University Of Pennsylvania |
Genetically modified immune cells targeting ny-eso-1 and methods of use thereof
|
|
EP3724327A4
(en)
*
|
2017-12-14 |
2022-01-12 |
EZY Biotech LLC |
SUBJECT-SPECIFIC TUMOR INHIBITION CELLS AND THEIR USE
|
|
EP3724214A4
(en)
|
2017-12-15 |
2021-09-01 |
The Broad Institute Inc. |
SYSTEMS AND METHODS FOR PREDICTING REPAIR RESULTS IN GENETIC ENGINEERING
|
|
ES2952978T3
(es)
|
2018-03-14 |
2023-11-07 |
Arbor Biotechnologies Inc |
Sistemas y enzimas novedosos de direccionamiento a ADN de CRISPR
|
|
BR112020018658A2
(pt)
|
2018-03-15 |
2020-12-29 |
KSQ Therapeutics, Inc. |
Composições de regulação gênica e métodos para imu-noterapia aprimorada
|
|
US20210017509A1
(en)
*
|
2018-03-23 |
2021-01-21 |
The Trustees Of Columbia University In The City Of New York |
Gene Editing for Autosomal Dominant Diseases
|
|
MA52656A
(fr)
|
2018-04-05 |
2021-02-17 |
Editas Medicine Inc |
Procédés de production de cellules exprimant un récepteur recombinant et compositions associées
|
|
SG11202009446TA
(en)
|
2018-04-05 |
2020-10-29 |
Juno Therapeutics Inc |
T cells expressing a recombinant receptor, related polynucleotides and methods
|
|
RU2020135968A
(ru)
|
2018-04-05 |
2022-05-06 |
Джуно Терапьютикс, Инк. |
T-клеточные рецепторы и модифицированные клетки, экспрессирующие
|
|
EP3775213A1
(en)
*
|
2018-04-13 |
2021-02-17 |
Sigma Aldrich Co. LLC |
Modification of immune-related genomic loci using paired crispr nickase ribonucleoproteins
|
|
BR112020021903A2
(pt)
|
2018-04-27 |
2021-03-02 |
Rocket Pharmaceuticals, Ltd. |
terapia genética para degeneração do snc
|
|
CA3091490A1
(en)
|
2018-04-27 |
2019-10-31 |
Seattle Children's Hospital (dba Seattle Children's Research Institute) |
Rapamycin resistant cells
|
|
JP7542441B2
(ja)
|
2018-05-11 |
2024-08-30 |
クリスパー セラピューティクス アクチェンゲゼルシャフト |
癌を治療するための方法及び組成物
|
|
WO2019226953A1
(en)
|
2018-05-23 |
2019-11-28 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
BR112020025439A2
(pt)
|
2018-06-14 |
2021-03-16 |
Bluebird Bio, Inc. |
Receptores de antígenos quiméricos cd79a
|
|
CN108866004A
(zh)
*
|
2018-06-26 |
2018-11-23 |
奥妙生物技术（广州）有限公司 |
Shp-1敲除的t细胞及其构建方法
|
|
CA3105953A1
(en)
|
2018-07-09 |
2020-01-16 |
Flagship Pioneering Innovations V, Inc. |
Fusosome compositions and uses thereof
|
|
CN112823011A
(zh)
*
|
2018-07-09 |
2021-05-18 |
加利福尼亚大学董事会 |
基于t细胞的免疫疗法的基因靶标
|
|
KR20200011899A
(ko)
*
|
2018-07-25 |
2020-02-04 |
주식회사 툴젠 |
인위적인 유전자 조작을 통한 자가면역질환 치료
|
|
EP3827847A4
(en)
*
|
2018-07-26 |
2023-07-19 |
Toolgen Incorporated |
GENE EDITING OF ANTICOAGULANTS
|
|
WO2020041380A1
(en)
|
2018-08-20 |
2020-02-27 |
The Broad Institute, Inc. |
Methods and compositions for optochemical control of crispr-cas9
|
|
WO2020051283A1
(en)
|
2018-09-05 |
2020-03-12 |
The Regents Of The University Of California |
Generation of heritably gene-edited plants without tissue culture
|
|
US20200080056A1
(en)
*
|
2018-09-06 |
2020-03-12 |
The Trustees Of The University Of Pennsylvania |
CRISPR-Cas9 Knock-out of SHP-1/2 to Reduce T cell Exhaustion in Adoptive Cell Therapy
|
|
CN112654245B
(zh)
*
|
2018-09-11 |
2022-05-27 |
得克萨斯州大学系统董事会 |
自身免疫不良事件和免疫检查点阻断治疗的遗传小鼠模型
|
|
AU2019346335B2
(en)
|
2018-09-28 |
2024-07-25 |
Massachusetts Institute Of Technology |
Collagen-localized immunomodulatory molecules and methods thereof
|
|
WO2020072059A1
(en)
*
|
2018-10-04 |
2020-04-09 |
Bluebird Bio, Inc. |
Cblb endonuclease variants, compositions, and methods of use
|
|
US12331320B2
(en)
|
2018-10-10 |
2025-06-17 |
The Research Foundation For The State University Of New York |
Genome edited cancer cell vaccines
|
|
AU2019362879A1
(en)
*
|
2018-10-16 |
2021-05-27 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunotherapy
|
|
WO2020088450A1
(zh)
*
|
2018-10-29 |
2020-05-07 |
中国农业大学 |
新型CRISPR/Cas12f酶和系统
|
|
US12281338B2
(en)
|
2018-10-29 |
2025-04-22 |
The Broad Institute, Inc. |
Nucleobase editors comprising GeoCas9 and uses thereof
|
|
US12264323B2
(en)
|
2018-12-17 |
2025-04-01 |
The Broad Institute, Inc. |
CRISPR CPF1 direct repeat variants
|
|
WO2020131862A1
(en)
|
2018-12-17 |
2020-06-25 |
The Broad Institute, Inc. |
Crispr-associated transposase systems and methods of use thereof
|
|
US12351837B2
(en)
|
2019-01-23 |
2025-07-08 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US20220096551A1
(en)
*
|
2019-01-28 |
2022-03-31 |
Bar Ilan University |
Combinations, nanoparticles and methods for controlling natural killer cell activation and function
|
|
JP2022520402A
(ja)
|
2019-02-15 |
2022-03-30 |
エディタス・メディシン、インコーポレイテッド |
免疫療法のための改変ナチュラルキラー（ｎｋ）細胞
|
|
DE112020001306T5
(de)
|
2019-03-19 |
2022-01-27 |
Massachusetts Institute Of Technology |
Verfahren und zusammensetzungen zur editierung von nukleotidsequenzen
|
|
CN113966401A
(zh)
|
2019-04-10 |
2022-01-21 |
犹他大学研究基金会 |
用于治疗amd的htra1调节
|
|
US12473543B2
(en)
|
2019-04-17 |
2025-11-18 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
US20220249558A1
(en)
|
2019-04-30 |
2022-08-11 |
Crispr Therapeutics Ag |
Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19
|
|
BR112021021075A2
(pt)
|
2019-05-01 |
2021-12-14 |
Editas Medicine Inc |
Células que expressam um receptor recombinante de um locus de tgfbr2 modificado, polinucleotídeos relacionados e métodos
|
|
KR20220016474A
(ko)
|
2019-05-01 |
2022-02-09 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 ｃｄ247 유전자 자리로부터 키메라 수용체를 발현하는 세포, 관련 폴리뉴클레오타이드 및 방법
|
|
PE20221123A1
(es)
|
2019-05-03 |
2022-07-13 |
Specific Biologics Inc |
Endonucleasa de escision dual encapsulada en lipidos para edicion de genes y adn
|
|
US20220235340A1
(en)
|
2019-05-20 |
2022-07-28 |
The Broad Institute, Inc. |
Novel crispr-cas systems and uses thereof
|
|
US12188045B2
(en)
|
2019-06-07 |
2025-01-07 |
KSQ Therapeutics, Inc. |
Guide RNA combinations and methods of use
|
|
US20220280567A1
(en)
*
|
2019-06-14 |
2022-09-08 |
2Seventy Bio, Inc. |
Compositions and methods for treating cancer
|
|
EP3990491A1
(en)
|
2019-06-26 |
2022-05-04 |
Massachusetts Institute of Technology |
Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
|
|
US12344850B2
(en)
|
2019-07-30 |
2025-07-01 |
Pairwise Plants Services, Inc. |
Morphogenic regulators and methods of using the same
|
|
WO2021041922A1
(en)
|
2019-08-30 |
2021-03-04 |
The Broad Institute, Inc. |
Crispr-associated mu transposase systems
|
|
WO2021061648A1
(en)
|
2019-09-23 |
2021-04-01 |
Massachusetts Institute Of Technology |
Methods and compositions for stimulation of endogenous t cell responses
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
EP4028521A1
(en)
*
|
2019-12-09 |
2022-07-20 |
Caribou Biosciences, Inc. |
Crispr abasic restricted nucleotides and crispr accuracy via analogs
|
|
KR102673828B1
(ko)
*
|
2020-01-23 |
2024-06-10 |
주식회사 강스템바이오텍 |
off-the-shelf 줄기세포 및 면역세포, 이를 포함하는 약학적 조성물
|
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
ＮＰＭ１ｃ陽性がんの免疫療法のための組成物および方法
|
|
US20230165909A1
(en)
|
2020-04-21 |
2023-06-01 |
Aspen Neuroscience, Inc. |
Gene editing of lrrk2 in stem cells and method of use of cells differentiated therefrom
|
|
WO2021216622A1
(en)
|
2020-04-21 |
2021-10-28 |
Aspen Neuroscience, Inc. |
Gene editing of gba1 in stem cells and method of use of cells differentiated therefrom
|
|
US12433954B2
(en)
|
2020-05-01 |
2025-10-07 |
Massachusetts Institute Of Technology |
Methods of activating anti-CD19 chimeric antigen receptor (CAR) T cells using amphiphilic ligand conjugates comprising CAR-targeting protein sequence motifs
|
|
US20210340524A1
(en)
|
2020-05-01 |
2021-11-04 |
Massachusetts Institute Of Technology |
Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
|
|
JP2023525304A
(ja)
|
2020-05-08 |
2023-06-15 |
ザ ブロード インスティテュート，インコーポレーテッド |
標的二本鎖ヌクレオチド配列の両鎖同時編集のための方法および組成物
|
|
EP4146800A1
(en)
*
|
2020-05-08 |
2023-03-15 |
Metagenomi, Inc. |
Enzymes with ruvc domains
|
|
EP4150057A2
(en)
|
2020-05-13 |
2023-03-22 |
Juno Therapeutics, Inc. |
Process for producing donor-batched cells expressing a recombinant receptor
|
|
CA3178670A1
(en)
*
|
2020-06-03 |
2021-12-09 |
Lucas Benjamin HARRINGTON |
Programmable nucleases and methods of use
|
|
EP4171616A1
(en)
|
2020-06-26 |
2023-05-03 |
Juno Therapeutics GmbH |
Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods
|
|
US11332744B1
(en)
|
2020-10-26 |
2022-05-17 |
Arsenal Biosciences, Inc. |
Safe harbor loci
|
|
KR20230090367A
(ko)
|
2020-11-04 |
2023-06-21 |
주노 쎄러퓨티크스 인코퍼레이티드 |
변형된 불변 cd3 이뮤노글로불린 슈퍼패밀리 쇄 유전자좌로부터 키메라 수용체를 발현하는 세포 및 관련 폴리뉴클레오티드 및 방법
|
|
US11591381B2
(en)
|
2020-11-30 |
2023-02-28 |
Crispr Therapeutics Ag |
Gene-edited natural killer cells
|
|
WO2022132756A1
(en)
*
|
2020-12-14 |
2022-06-23 |
Emendobio Inc. |
Biallelic knockout of trac
|
|
EP4271798A1
(en)
|
2020-12-30 |
2023-11-08 |
CRISPR Therapeutics AG |
Compositions and methods for differentiating stem cells into nk cells
|
|
CN117413062A
(zh)
*
|
2021-02-01 |
2024-01-16 |
爱普思伦生物公司 |
基因沉默
|
|
WO2022170059A1
(en)
|
2021-02-05 |
2022-08-11 |
Christiana Care Health Services, Inc. |
Methods of and compositions for reducing gene expression and/or activity
|
|
US20240108654A1
(en)
|
2021-03-03 |
2024-04-04 |
Juno Therapeutics, Inc. |
Combination of a t cell therapy and a dgk inhibitor
|
|
AU2022244229A1
(en)
|
2021-03-22 |
2023-09-14 |
Juno Therapeutics, Inc. |
Method to assess potency of viral vector particles
|
|
WO2022215982A1
(ko)
*
|
2021-04-05 |
2022-10-13 |
주식회사 셀렌진 |
Trac 유전자에 상보적인 가이드 rna 및 이의 용도
|
|
WO2022232839A1
(en)
|
2021-04-30 |
2022-11-03 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for improved production of primary cd34+ cells
|
|
EP4355879A4
(en)
|
2021-06-14 |
2025-07-23 |
Kamau Therapeutics Inc |
METHODS FOR GENETIC MODIFICATION OF HEMATOPOIETIC STEM AND PROGENITOR CELLS FOR ERYTHROCYTE-SPECIFIC EXPRESSION OF THERAPEUTIC PROTEINS
|
|
US20230016422A1
(en)
*
|
2021-06-23 |
2023-01-19 |
Crispr Therapeutics Ag |
Engineered cells with improved protection from natural killer cell killing
|
|
EP4362957A1
(en)
|
2021-07-01 |
2024-05-08 |
Indapta Therapeutics, Inc. |
Engineered natural killer (nk) cells and related methods
|
|
CA3227105A1
(en)
|
2021-07-30 |
2023-02-02 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of methyl-cpg binding protein 2 (mecp2)
|
|
US20240254483A1
(en)
|
2021-07-30 |
2024-08-01 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating expression of frataxin (fxn)
|
|
WO2023028348A1
(en)
|
2021-08-27 |
2023-03-02 |
Metagenomi, Inc. |
Enzymes with ruvc domains
|
|
CA3232968A1
(en)
|
2021-10-14 |
2023-04-20 |
Jasper Williams |
Immune cells having co-expressed shrnas and logic gate systems
|
|
US20250066816A1
(en)
|
2021-11-01 |
2025-02-27 |
Sigma-Aldrich Co. Llc |
Electroporation enhancers for crispr-cas systems
|
|
WO2023081715A1
(en)
|
2021-11-03 |
2023-05-11 |
Viracta Therapeutics, Inc. |
Combination of car t-cell therapy with btk inhibitors and methods of use thereof
|
|
WO2023081900A1
(en)
|
2021-11-08 |
2023-05-11 |
Juno Therapeutics, Inc. |
Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods
|
|
EP4448549A2
(en)
|
2021-12-17 |
2024-10-23 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae fusion glycoproteins
|
|
WO2023115041A1
(en)
|
2021-12-17 |
2023-06-22 |
Sana Biotechnology, Inc. |
Modified paramyxoviridae attachment glycoproteins
|
|
IL313660A
(en)
|
2021-12-22 |
2024-08-01 |
Camp4 Therapeutics Corp |
Modulation of gene transcription using antisense oligonucleotides targeting regulatory RNAs
|
|
EP4463135A2
(en)
|
2022-01-10 |
2024-11-20 |
Sana Biotechnology, Inc. |
Methods of ex vivo dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
EP4463548A1
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene activation
|
|
EP4463549A2
(en)
|
2022-01-14 |
2024-11-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for programming t cell phenotypes through targeted gene repression
|
|
US20250152709A1
(en)
|
2022-02-01 |
2025-05-15 |
Sana Biotechnology, Inc. |
Cd3-targeted lentiviral vectors and uses thereof
|
|
US20250144235A1
(en)
|
2022-02-02 |
2025-05-08 |
Sana Biotechnology, Inc. |
Methods of repeat dosing and administration of lipid particles or viral vectors and related systems and uses
|
|
WO2023201133A1
(en)
|
2022-04-14 |
2023-10-19 |
Board Of Regents Of The University Of Nebraska |
Cell therapy for alzheimer's disease
|
|
WO2023224715A1
(en)
|
2022-05-19 |
2023-11-23 |
Massachusetts Institute Of Technology |
Car cells targeting an inserted ligand
|
|
WO2023250511A2
(en)
|
2022-06-24 |
2023-12-28 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for reducing low-density lipoprotein through targeted gene repression
|
|
CA3259982A1
(en)
|
2022-06-30 |
2024-01-04 |
Indapta Therapeutics Inc |
COMBINATION OF MODIFIED NATURAL KILLER (NK) CELLS AND ANTIBODY THERAPY AND ASSOCIATED METHODS
|
|
CA3261865A1
(en)
|
2022-07-12 |
2024-01-18 |
Tune Therapeutics Inc |
TARGETED TRANSCRIPTIONAL ACTIVATION COMPOSITIONS, SYSTEMS AND METHODS
|
|
CA3264214A1
(en)
|
2022-08-19 |
2024-02-22 |
Tune Therapeutics Inc |
Compositions, systems and methods of regulating the hepatitis B virus by targeted gene suppression
|
|
WO2024044655A1
(en)
|
2022-08-24 |
2024-02-29 |
Sana Biotechnology, Inc. |
Delivery of heterologous proteins
|
|
JP2025531850A
(ja)
|
2022-09-08 |
2025-09-25 |
ジュノー セラピューティクス インコーポレイテッド |
Ｔ細胞療法および継続的または間欠的ｄｇｋ阻害剤投薬の組合せ
|
|
AU2023347814A1
(en)
*
|
2022-09-19 |
2025-04-10 |
Emendobio Inc. |
Biallelic knockout of ctla4
|
|
CN120239746A
(zh)
|
2022-09-19 |
2025-07-01 |
图恩疗法股份有限公司 |
用于调节t细胞功能的组合物、系统和方法
|
|
EP4590688A1
(en)
|
2022-09-21 |
2025-07-30 |
Sana Biotechnology, Inc. |
Lipid particles comprising variant paramyxovirus attachment glycoproteins and uses thereof
|
|
EP4602174A1
(en)
|
2022-10-13 |
2025-08-20 |
Sana Biotechnology, Inc. |
Viral particles targeting hematopoietic stem cells
|
|
WO2024100604A1
(en)
|
2022-11-09 |
2024-05-16 |
Juno Therapeutics Gmbh |
Methods for manufacturing engineered immune cells
|
|
EP4627096A1
(en)
|
2022-12-02 |
2025-10-08 |
Sana Biotechnology, Inc. |
Lipid particles with cofusogens and methods of producing and using the same
|
|
WO2024163683A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Systems, compositions, and methods for modulating expression of methyl-cpg binding protein 2 (mecp2) and x-inactive specific transcript (xist)
|
|
WO2024163678A2
(en)
|
2023-02-01 |
2024-08-08 |
Tune Therapeutics, Inc. |
Fusion proteins and systems for targeted activation of frataxin (fxn) and related methods
|
|
EP4658675A1
(en)
|
2023-02-03 |
2025-12-10 |
C3S2 GmbH |
Methods for non-viral manufacturing of engineered immune cells
|
|
TW202442689A
(zh)
|
2023-03-03 |
2024-11-01 |
美商亞森諾生物科學公司 |
靶向ｐｓｍａ及ｃａ９之系統
|
|
WO2024220574A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Universal protein g fusogens and adapter systems thereof and related lipid particles and uses
|
|
WO2024220598A2
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Lentiviral vectors with two or more genomes
|
|
WO2024220560A1
(en)
|
2023-04-18 |
2024-10-24 |
Sana Biotechnology, Inc. |
Engineered protein g fusogens and related lipid particles and methods thereof
|
|
AU2024274792A1
(en)
|
2023-05-23 |
2025-10-23 |
Sana Biotechnology, Inc. |
Tandem fusogens and related lipid particles
|
|
WO2024249342A1
(en)
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting ptpn2 expression
|
|
WO2024249348A2
(en)
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting fl1-1 expression
|
|
WO2024249346A1
(en)
|
2023-05-26 |
2024-12-05 |
Editas Medicine, Inc. |
Crispr-related methods and compositions targeting cd70 expression
|
|
CN116539885B
(zh)
*
|
2023-07-06 |
2023-09-29 |
上海秤信生物科技有限公司 |
用于乳腺癌早期检测的肿瘤自身抗原/抗体组合及应用
|
|
WO2025029840A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for multiplexed activation and repression of t cell gene expression
|
|
WO2025029835A1
(en)
|
2023-07-31 |
2025-02-06 |
Tune Therapeutics, Inc. |
Compositions and methods for modulating il-2 gene expression
|
|
WO2025038494A1
(en)
|
2023-08-11 |
2025-02-20 |
Tune Therapeutics, Inc. |
Compositions, systems, and methods for lymphoid cell differentiation using targeted gene activation
|
|
WO2025054202A1
(en)
|
2023-09-05 |
2025-03-13 |
Sana Biotechnology, Inc. |
Method of screening a sample comprising a transgene with a unique barcode
|
|
WO2025059073A1
(en)
|
2023-09-11 |
2025-03-20 |
Tune Therapeutics, Inc. |
Epigenetic editing methods and systems for differentiating stem cells
|
|
WO2025059533A1
(en)
|
2023-09-13 |
2025-03-20 |
The Broad Institute, Inc. |
Crispr enzymes and systems
|
|
WO2025096638A2
(en)
|
2023-10-30 |
2025-05-08 |
Turnstone Biologics Corp. |
Genetically modified tumor infilitrating lymphocytes and methods of producing and using the same
|
|
WO2025117544A1
(en)
|
2023-11-29 |
2025-06-05 |
The Broad Institute, Inc. |
Engineered omega guide molecule and iscb compositions, systems, and methods of use thereof
|
|
WO2025137646A1
(en)
|
2023-12-22 |
2025-06-26 |
Recode Therapeutics, Inc. |
Gene editing methods and compositions for treating cystic fibrosis
|
|
WO2025151838A1
(en)
|
2024-01-12 |
2025-07-17 |
Sana Biotechnology, Inc. |
Safety switches to control in vitro and in vivo proliferation of cell therapy products
|
|
WO2025184529A1
(en)
|
2024-03-01 |
2025-09-04 |
Sana Biotechnology, Inc. |
Viral particles with fusogen display and related compositions and methods
|
|
WO2025212519A1
(en)
|
2024-04-01 |
2025-10-09 |
Moonlight Bio, Inc. |
Dll3 binding proteins and uses thereof
|
|
WO2025213127A1
(en)
|
2024-04-05 |
2025-10-09 |
Indapta Therapeutics, Inc. |
Treatment of autoimmune diseases or conditions with natural killer cells
|
|
US20250345431A1
(en)
|
2024-05-10 |
2025-11-13 |
Juno Therapeutics, Inc. |
Genetically engineered t cells expressing a cd19 chimeric antigen receptor (car) and uses thereof for allogeneic cell therapy
|
|
WO2025245399A1
(en)
|
2024-05-23 |
2025-11-27 |
Indapta Therapeutics, Inc. |
Method of treating cancer with natural killer cells
|